IMAB – I-Mab ADR
I-MABIMAB
$5.33Name : I-MAB
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $614,368,064.00
EPSttm : -0.51
I-MAB
$5.33
21.97%$0.96Float Short %
3.42
Margin Of Safety %
Put/Call OI Ratio
0.42
EPS Next Q Diff
0.02
EPS Last/This Y
-0.04
EPS This/Next Y
-0.03
Price
4.37
Target Price
7
Analyst Recom
1
Performance Q
89.18
Relative Volume
0.5
Beta
1.43
Ticker: IMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | IMAB | 4.28 | 0.16 | 0.64 | 6952 |
| 2025-09-09 | IMAB | 4.62 | 0.17 | 0.00 | 7197 |
| 2025-09-10 | IMAB | 4.23 | 0.17 | 0.96 | 7289 |
| 2025-09-11 | IMAB | 3.95 | 0.25 | 0.00 | 8044 |
| 2025-09-12 | IMAB | 4.08 | 0.25 | 0.00 | 8058 |
| 2025-09-15 | IMAB | 3.65 | 0.23 | 0.00 | 8591 |
| 2025-09-16 | IMAB | 3.72 | 0.23 | 0.24 | 8630 |
| 2025-09-17 | IMAB | 3.69 | 0.22532614861032 | 0 | 8641 |
| 2025-09-18 | IMAB | 3.65 | 0.23 | 0.00 | 8651 |
| 2025-09-19 | IMAB | 3.78 | 0.21 | 0.44 | 8569 |
| 2025-09-22 | IMAB | 3.87 | 0.32 | 0.01 | 3650 |
| 2025-09-23 | IMAB | 3.85 | 0.32 | 0.27 | 3716 |
| 2025-09-24 | IMAB | 3.54 | 0.32 | 0.22 | 3759 |
| 2025-09-25 | IMAB | 3.52 | 0.32 | 1.12 | 3838 |
| 2025-09-26 | IMAB | 3.52 | 0.35 | 0.69 | 4024 |
| 2025-09-29 | IMAB | 3.41 | 0.35 | 0.00 | 4063 |
| 2025-09-30 | IMAB | 3.79 | 0.35 | 0.00 | 4111 |
| 2025-10-01 | IMAB | 3.87 | 0.36 | 0.00 | 4012 |
| 2025-10-02 | IMAB | 4.15 | 0.36 | 1.67 | 4020 |
| 2025-10-03 | IMAB | 4.34 | 0.37 | 0.62 | 4094 |
| 2025-10-06 | IMAB | 4.32 | 0.38 | 0.87 | 4209 |
| 2025-10-07 | IMAB | 4.3 | 0.42 | 0.21 | 4322 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | IMAB | 4.27 | - | - | -0.34 |
| 2025-09-09 | IMAB | 4.61 | - | - | -0.34 |
| 2025-09-10 | IMAB | 4.22 | - | - | -0.34 |
| 2025-09-11 | IMAB | 3.90 | - | - | -0.34 |
| 2025-09-12 | IMAB | 4.14 | - | - | -0.34 |
| 2025-09-15 | IMAB | 3.62 | - | - | -0.32 |
| 2025-09-16 | IMAB | 3.72 | - | - | -0.32 |
| 2025-09-17 | IMAB | 3.70 | - | - | -0.32 |
| 2025-09-18 | IMAB | 3.65 | - | - | -0.32 |
| 2025-09-19 | IMAB | 3.78 | - | - | -0.32 |
| 2025-09-22 | IMAB | 3.88 | - | - | -0.32 |
| 2025-09-23 | IMAB | 3.84 | - | - | -0.32 |
| 2025-09-24 | IMAB | 3.54 | - | - | -0.32 |
| 2025-09-25 | IMAB | 3.52 | - | - | -0.32 |
| 2025-09-26 | IMAB | 3.48 | - | - | -0.32 |
| 2025-09-29 | IMAB | 3.41 | - | - | -0.32 |
| 2025-09-30 | IMAB | 3.79 | - | - | -0.32 |
| 2025-10-01 | IMAB | 3.86 | - | - | -0.32 |
| 2025-10-02 | IMAB | 4.13 | - | - | -0.32 |
| 2025-10-03 | IMAB | 4.35 | - | - | -0.32 |
| 2025-10-06 | IMAB | 4.33 | - | - | -0.32 |
| 2025-10-07 | IMAB | 4.37 | - | - | -0.32 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-09-09 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-09-10 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-09-11 | IMAB | 0.00 | 9.81 | 3.12 |
| 2025-09-12 | IMAB | 0.00 | 9.81 | 3.12 |
| 2025-09-15 | IMAB | 0.00 | 9.78 | 3.12 |
| 2025-09-16 | IMAB | 0.00 | 9.78 | 3.12 |
| 2025-09-17 | IMAB | 0.00 | 9.78 | 3.12 |
| 2025-09-18 | IMAB | 0.00 | 9.78 | 3.12 |
| 2025-09-19 | IMAB | 0.00 | 9.78 | 3.12 |
| 2025-09-22 | IMAB | 0.00 | 9.78 | 3.12 |
| 2025-09-23 | IMAB | 0.00 | 9.78 | 3.12 |
| 2025-09-24 | IMAB | 0.00 | 9.78 | 3.12 |
| 2025-09-25 | IMAB | 0.00 | 9.78 | 3.43 |
| 2025-09-26 | IMAB | 0.00 | 9.78 | 3.42 |
| 2025-09-29 | IMAB | 0.00 | 9.76 | 3.42 |
| 2025-09-30 | IMAB | 0.00 | 9.76 | 3.42 |
| 2025-10-01 | IMAB | 0.00 | 9.76 | 3.42 |
| 2025-10-02 | IMAB | 0.00 | 9.76 | 3.42 |
| 2025-10-03 | IMAB | 0.00 | 9.76 | 3.42 |
| 2025-10-06 | IMAB | 0.00 | 0.82 | 3.42 |
| 2025-10-07 | IMAB | 0.00 | 0.82 | 3.42 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.07
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.05
Insider Transactions
Institutional Transactions
0.82
Beta
1.43
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
11
Growth Score
18
Sentiment Score
96
Actual DrawDown %
94.9
Max Drawdown 5-Year %
-99.3
Target Price
7
P/E
Forward P/E
PEG
P/S
P/B
1.76
P/Free Cash Flow
EPS
-0.71
Average EPS Est. Cur. Y
-0.32
EPS Next Y. (Est.)
-0.35
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.5
Return on Equity vs Sector %
-45.5
Return on Equity vs Industry %
-31.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.12
EBIT Estimation
I-MABSector: Healthcare
Industry: Biotechnology
Employees: 32
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
stock quote shares IMAB – I-Mab ADR Stock Price stock today
news today IMAB – I-Mab ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMAB – I-Mab ADR yahoo finance google finance
stock history IMAB – I-Mab ADR invest stock market
stock prices IMAB premarket after hours
ticker IMAB fair value insiders trading